Z
Zymeworks D
D
ZYME
13.320
USD
-0.68
(-4.86%)
مغلق
حجم التداول
8,603
الربح لكل سهم
-2
العائد الربحي
-
P/E
-9
حجم السوق
996,928,807
الأخبار المقالات
العنوان: Zymeworks
القطاع: Healthcare
الصناعة: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.